6-methyl-5-nitro-1,3-dipropyl-1H-pyrimidine-2,4-dione | 157119-79-4

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 6-methyl-5-nitro-1,3-dipropyl-1H-pyrimidine-2,4-dione
• 英文别名: 6-methyl-5-nitro-1,3-dipropyluracil；6-methyl-5-nitro-1,3-dipropyl-1,3-dihydropyrimidine-2,4-dione；1,3-dipropyl-5-nitro-6-methyl-uracil；6-methyl-5-nitro-1,3-dipropylpyrimidine-2,4-dione
• CAS: 157119-79-4
• 化学式: C₁₁H₁₇N₃O₄
• 分子量: 255.274
• InChiKey: WRWQSJUSHNWSNL-UHFFFAOYSA-N

物化性质

• 沸点：
  336.4±45.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  86.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-methyl-5-nitro-1,3-dipropyl-1H-pyrimidine-2,4-dione 在 哌啶 、 甲酸 、 sodium dithionite 作用下， 以 1,4-二氧六环 为溶剂， 生成 [4-(2,4-Dioxo-1,3-dipropyl-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-phenoxy]-acetic acid
  参考文献：
  名称：

  Design, Synthesis, and Structure−Activity Relationships of 1-,3-,8-, and 9-Substituted-9-deazaxanthines at the Human A_2B Adenosine Receptor

  摘要：

  Over two hundred 1-, 3-, 8-, and 9-substituted-9-deazaxanthines were prepared and evaluated for their binding affinity at the recombinant human adenosine receptors, in particular at the hA(2B) and hA(2A) subtypes. Several ligands endowed with sub-micromolar to low nanomolar binding affinity at hA(2B) receptors, good selectivity over hA(2A) and hA(3), but a relatively poor selectivity over hA(1) were obtained. Good antagonistic potencies and efficacies, with pA(2) values close to the corresponding pK(i)s, were observed in functional assays in vitro performed on a selected series of compounds. 1,3-Dimethyl-8-phenoxy-(N-p-halogenophenyl)-acetamido-9-deazaxanthine derivatives appeared as the most interesting leads, some of them showing outstanding hA(2B) affinities, high selectivity over hA(2A) and hA(3), but low selectivity over hA(1). Structure-affinity relationships suggested that the binding potency at the hA(2B) receptor was mainly modulated by the steric (lipophilic) properties of the substituents at positions 1 and 3 and by the electronic and lipophilic characteristics of the substituents at position 8. A comparison among affinity and selectivity profiles of 9-deazaxanthines with the corresponding xanthines suggested some possible differences in their binding mode.

  DOI：

  10.1021/jm0506221
• 作为产物：
  描述：

  6-methyl-1,3-dipropyluracil 在 硫酸 、 硝酸 作用下， 生成 6-methyl-5-nitro-1,3-dipropyl-1H-pyrimidine-2,4-dione
  参考文献：
  名称：

  New pyrrolopyrimidin-6-yl benzenesulfonamides: Potent A2B adenosine receptor antagonists

  摘要：

  A new series of 4-(1,3-dialkyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-6-yl)benzenesulfonamides has been identified as potent AZB adenosine receptor antagonists. The products have been evaluated for their binding affinities for the human A(2B), A(1) and A(3) adenosine receptors. 6-(4-{[4-(4-Bromobenzyl)piperazin-1-yl]sulfonyl}phenyl)-1,3-dimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione (16) showed a high affinity for the AZB adenosine receptor (IC50 = 1 nM) and selectivity (A(1): 183x; A(30): 12660x). Synthesis and SAR of this novel class of compounds showing improved absorption properties is presented herein. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.074

文献信息

• Novel 1,3-Dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as Potent and Selective A_2B Adenosine Receptor Antagonists
  作者：Pier Giovanni Baraldi、Stefania Baraldi、Giulia Saponaro、Delia Preti、Romeo Romagnoli、Laura Piccagli、Andrea Cavalli、Maurizio Recanatini、Allan R. Moorman、Abdel Naser Zaid、Katia Varani、Pier Andrea Borea、Mojgan Aghazadeh Tabrizi

  DOI：10.1021/jm201292w

  日期：2012.1.26

  including the comparative molecular field analysis (CoMFA) method, on 52 antagonists of the A2B adenosine receptor with known biological activity were performed to identify the three-dimensional features responsible for A2B adenosine receptor antagonist activity. On the basis of these and previous results on the potent antagonist effect of 8-pyrazolyl-xanthines at human A2BAR, a new series of compounds

  对具有已知生物学活性的52种A 2B腺苷受体拮抗剂进行了分子建模研究，包括比较分子场分析（CoMFA）方法，以鉴定负责A 2B腺苷受体拮抗剂活性的三维特征。基于这些和先前关于8-吡唑基-黄嘌呤对人A 2B AR的强效拮抗作用的结果，合成了一系列新的化合物，并在针对人A 1，A 2A，A 3和A的结合研究中进行了评估。一个2B人工鱼礁。与以前的系列相比，选择性有了显着提高，保持了对人类A 2B的效力如8- [3-（4-氯-6-三氟甲基-1 H-苯并咪唑-2-基-甲氧基）-1-甲基-1 H-吡唑-5-基] -1所示，获得了受体。，3-二丙基-3,7-二氢嘌呤-2,6-二酮衍生物66：K i A 2B = 9.4 nM，IC 50 hA 2B = 26 nM hA 1 / hA 2B = 269，hA 2A / hA 2B > 106，hA 3 / hA 2B > 106。这项研究还导致鉴定了一
• [EN] NEW-4-(PYRROLOPYRIMIDIN-6-YL)BENZENESULPHONAMIDE DERIVATIVES<br/>[FR] NOUVEAUX DERIVES DE 4-(PYRROLOPYRIMIDIN-6-YL)BENZENESULPHONAMIDE
  申请人：ALMIRALL PRODESFARMA SA

  公开号：WO2003082873A1

  公开（公告）日：2003-10-09

  This invention is directed to new potent and selective antagonists of A2A and/or A2B adenosine receptors having the general formula (I) to process for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

  这项发明是针对新型高效选择性A2A和/或A2B腺苷受体拮抗剂的，其具有通用公式（I），用于其制备的过程；包含它们的药物组合物；以及它们在治疗中的应用。
• New-4-pyrrolopyrimidin-6-YL)benzenesulphonamide derivatives
  申请人：Vidal Juan Bernat

  公开号：US20050261248A1

  公开（公告）日：2005-11-24

  This invention is directed to selective antagonists of A 2A and/or A 2B adenosine receptors having the general formula (I); to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

  本发明涉及选择性A2A和/或A2B腺苷受体拮抗剂，其具有一般式（I）；它们的制备方法；包括它们的药物组合物；以及它们在治疗中的使用。
• A2B adenosine receptor antagonists
  申请人：Kalla Rao

  公开号：US20050119287A1

  公开（公告）日：2005-06-02

  Disclosed are novel compounds that are A 2B adenosine receptor antagonists having the following structure: wherein R 1 and R 2 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, and R 4 is an optionally substituted heteroaryl moiety. The compounds of the invention are useful for treating various disease states, including asthma, chronic obstructive pulmonary disorder, pulmonary inflammation, emphysema, diabetic disorders, inflammatory gastrointestinal tract disorders, immunological/inflammatory disorders, cardiovascular diseases, neurological disorders, and diseases related to angiogenesis.

  本发明涉及一种新的化合物，该化合物是A2B腺苷受体拮抗剂，其结构如下：其中R1和R2独立地选择自氢、可选择性取代的烷基、可选择性取代的环烷基、可选择性取代的芳基和可选择性取代的杂环芳基，而R4是可选择性取代的杂环芳基基团。本发明的化合物可用于治疗各种疾病状态，包括哮喘、慢性阻塞性肺疾病、肺部炎症、肺气肿、糖尿病性疾病、炎症性胃肠道疾病、免疫/炎症性疾病、心血管疾病、神经系统疾病和与血管生成相关的疾病。
• 6-Phenyldihydropyrrolopyrimidinedione derivatives
  申请人：Vidal Juan Bernat

  公开号：US20050070558A1

  公开（公告）日：2005-03-31

  6-phenylpyrrolopyrimidinedione derivatives of the formula (I), and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 are organic residues, L 1 is a spacer group and R 6 is C(O) NR 10 R 11 , —S(O) 2 NR 10 R 11 , ? —ON═CR 12 R 13 , or a heterocyclyl, aryl? or heteroaryl group, where R 10 , R 11 , R 12 and R 13 are organic residues, have therapeutic potential as A2 adenosine receptor inhibitors.

  式(I)的6-苯基吡咯嘧啶二酮衍生物及其药学上可接受的盐，其中R1、R2、R3、R4和R5均为有机残基，L1为间隔基，R6为C（O）NR10R11、—S（O）2NR10R11、？—ON═CR12R13或杂环基、芳基或杂芳基，其中R10、R11、R12和R13为有机残基，具有作为A2腺苷受体抑制剂的治疗潜力。